Doravirine/lamivudine/tenofovir disoproxil

Doravirine/lamivudine/tenofovir disoproxil is a fixed-dose combination of antiretroviral medications used in the treatment of HIV/AIDS. It contains three active ingredients: doravirine, lamivudine, and tenofovir disoproxil. This combination is marketed under the brand name Delstrigo by Merck.

Composition

The combination drug contains three active ingredients:

• Doravirine: A non-nucleoside reverse transcriptase inhibitor (NNRTI) that prevents the HIV virus from replicating in the body.
• Lamivudine: A nucleoside reverse transcriptase inhibitor (NRTI) that works by interfering with the normal functioning of the HIV virus.
• Tenofovir disoproxil: Another NRTI that helps to decrease the amount of HIV in the body, thereby helping the immune system to work better.

Usage

Doravirine/lamivudine/tenofovir disoproxil is used in the treatment of HIV-1 infection in adults. It is used in combination with other antiretroviral agents. The drug is taken orally, once daily, with or without food.

Side Effects

Common side effects of Doravirine/lamivudine/tenofovir disoproxil include nausea, diarrhea, headache, fatigue, and abdominal pain. Serious side effects may include lactic acidosis, severe hepatomegaly with steatosis, and post treatment acute exacerbation of hepatitis B.

Precautions

Before starting treatment with Doravirine/lamivudine/tenofovir disoproxil, patients should be tested for hepatitis B virus infection. Patients with renal impairment, hepatic impairment, or who are co-infected with hepatitis B or C should be monitored closely during treatment.

See Also

• Antiretroviral therapy
• HIV/AIDS
• Reverse transcriptase inhibitor

‎